Mersana Therapeutics, Inc.
MRSN
$7.65
-$0.10-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.28% | -70.21% | 52.89% | 63.65% | -78.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.28% | -70.21% | 52.89% | 63.65% | -78.48% |
| Cost of Revenue | -5.96% | -1.85% | 3.68% | -51.51% | -64.78% |
| Gross Profit | 11.97% | -65.10% | 45.11% | 90.34% | 60.98% |
| SG&A Expenses | -29.40% | -22.79% | -12.31% | -23.50% | -42.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.83% | -9.85% | -1.44% | -43.20% | -58.68% |
| Operating Income | 19.16% | -16.72% | 29.23% | 66.22% | 54.95% |
| Income Before Tax | -0.12% | -24.95% | 27.77% | 73.39% | 55.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.12% | -24.95% | 27.77% | 72.39% | 55.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.12% | -24.95% | 27.77% | 72.39% | 55.31% |
| EBIT | 19.16% | -16.72% | 29.23% | 66.22% | 54.95% |
| EBITDA | 19.01% | -17.58% | 29.64% | 66.95% | 55.41% |
| EPS Basic | 1.67% | -21.90% | 29.49% | 72.89% | 57.81% |
| Normalized Basic EPS | 17.62% | -21.90% | 27.64% | 67.45% | 57.81% |
| EPS Diluted | 1.67% | -21.90% | 29.49% | 72.89% | 57.81% |
| Normalized Diluted EPS | 17.62% | -21.90% | 27.64% | 67.45% | 57.81% |
| Average Basic Shares Outstanding | 1.82% | 2.50% | 2.44% | 1.83% | 5.91% |
| Average Diluted Shares Outstanding | 1.82% | 2.50% | 2.44% | 1.83% | 5.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |